𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Six-Week Open-Label Reboxetine Treatment in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

✍ Scribed by Ratner, Sharon; Laor, Nathaniel; Bronstein, Yifat; Weizman, Abraham; Toren, Paz

Book ID
123173436
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
96 KB
Volume
44
Category
Article
ISSN
1527-5418

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Duloxetine in the treatment of adolescen
Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: an open-label study
✍ Javad Mahmoudi-Gharaei; Nasrin Dodangi; Mehdi Tehrani-Doost; Toktam Faghihi πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 90 KB πŸ‘ 2 views

Objective The main aim of this study was to explore the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in the treatment of adolescents with attention deficit/hyperactivity disorder (ADHD). Methods Seventeen adolescents aged 11-18 years, diagnosed with ADHD, par

Diagnosis and Treatment of Children and
Diagnosis and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
✍ Michael B. Brown πŸ“‚ Article πŸ“… 2000 πŸ› American Counseling Association 🌐 English βš– 384 KB πŸ‘ 1 views

Attention‐deficit/hyperactive disorder (ADHD) has been estimated to affect between 3% and 5% of school‐age children. The disorder frequently has a profound effect on a child's personal, social and academic development and is a risk factor in the development of other comorbid disorders. Diagnostic cr